¼¼°èÀÇ Çã´Ï µå·¹½Ì ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : À¯Çüº°, Á¦Ç°º°, »óó À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° ºÎ¹® ¿¹Ãø(2024-2030³â)
Honey Dressing Market Size, Share & Trends Analysis Report By Type (Non-adhesive, Adhesive), By Product (Honey Impregnated Gauze, Honey Gel Sheets), By Wound Type (Chronic Wounds, Acute Wounds), By End-use, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå
:
1571415
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2024³â 09¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 120 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
Çã´Ï µå·¹½Ì ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¼¼°è Çã´Ï µå·¹½Ì ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 4,707¸¸ ´Þ·¯¿¡ À̸£°í, 2024³âºÎÅÍ 2030³â±îÁöÀÇ CAGRÀº 4.91%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ ½ÃÀåÀ» Å©°Ô °ßÀÎÇϰí ÀÖ´Â °ÍÀº ¸¸¼º »óóÀÇ À¯º´·ü Áõ°¡¿Í, »óó Äɾ ÀÖ¾î¼ÀÇ ²ÜÀÇ Ä¡·á È¿°ú¿¡ ´ëÇÑ ÀǽÄÀÇ °íÁ¶ÀÔ´Ï´Ù. ´ç´¢º´¼º ±Ë¾ç, Á¤¸Æ¼º Çã¹÷Áö ±Ë¾ç, ¿åâ°ú °°Àº ¸¸¼º »óó´Â °í·ÉÈ ¹× ´ç´¢º´ ÀÌȯÀ² Áõ°¡¿Í °°Àº ¿äÀÎÀ¸·Î ÀÎÇØ ´õ ÈçÇØÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ ½ÉÀåÇùȸ(AHA)°¡ 2024³â 1¿ù¿¡ ¹ßÇ¥ÇÑ ¹Ù¿¡ µû¸£¸é ´ç´¢º´À¸·Î Áø´ÜµÇÁö ¾ÊÀº ¼ºÀÎÀº 970¸¸¸í, ´ç´¢º´À¸·Î Áø´Ü¹ÞÀº ¼ºÀÎÀº 2,930¸¸¸íÀÔ´Ï´Ù.
ÀÇ·á Á¾»çÀÚ¿Í È¯ÀÚ »çÀÌ¿¡¼ õ¿¬ Á¦Ç°°ú À¯±â³ó Á¦Ç°¿¡ ´ëÇÑ ¼±È£°¡ ³ô¾ÆÁö°í ÀÖ´Â °ÍÀÌ ½ÃÀåÀÇ Å« ÃËÁø¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ²ÜÀº ³ôÀº ´çºÐ ÇÔ·®, ³·Àº pH ¹× °ú»êȼö¼ÒÀÇ Á¸Àç·Î ÀÎÇØ Ç×±Õ Æ¯¼ºÀÌ ÀÎÁ¤µÇ¾úÀ¸¸ç ±¤¹üÀ§ÇÑ º´¿ø±Õ¿¡ È¿°úÀûÀÔ´Ï´Ù. 2023³â 3¿ù, International Wound JournalÀº ´ç´¢º´¼º ±Ë¾ç(DFU)ÀÇ Ä¡·á¿¡ Çã´Ï µå·¹½Ì(HD)ÀÇ ¿µÇâÀ» Æò°¡ÇÏ´Â ¸ÞŸ ºÐ¼®À» ½Ç½ÃÇÑ ¿¬±¸¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ±× °á°ú, DFU¿¡ HD¸¦ »ç¿ëÇϸé, ´ëÁ¶±º¿¡ ºñÇØ »óó Ä¡À¯À²ÀÌ ÇöÀúÇÏ°Ô Çâ»óµÇ¾î, »óó Ä¡À¯¿¡ ÇÊ¿äÇÑ ½Ã°£ÀÌ ´ÜÃàµÇ´Â °ÍÀÌ ÆÇ¸íµÇ¾ú½À´Ï´Ù.
COVID-19ÀÇ À¯ÇàÀº ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. À¯ÇàÀº ¼¼°è °ø±Þ¸ÁÀÇ Áß´ÜÀ» ÀÏÀ¸ÄÑ Çã´Ï µå·¹½ÌÀÇ »ý»ê°ú À¯Åë¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. Àá±Ý, À̵¿ Á¦ÇÑ ¹× ³ëµ¿·Â °¨¼Ò°¡ Á¦Á¶ ¹× ÃâÇÏ Áö¿¬À¸·Î À̾îÁ³½À´Ï´Ù. À¯Çà Áß¿¡´Â °¨¿° ´ëÃ¥¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁ® Ç×±Õ Æ¯¼ºÀ» °¡Áø »óó Äɾî Á¦Ç°¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁ³½À´Ï´Ù. Ç×±Õ È¿°ú·Î ¾Ë·ÁÁø Çã´Ï µå·¹½ÌÀº »óó °¨¿° ¿¹¹æ¿¡ ÃÊÁ¡À» ¸ÂÃá ½ÃÀåÀÇ Æ¯Á¤ ºÐ¾ß¿¡¼ ÁÖ¸ñµµ°¡ ³ô¾ÆÁ³½À´Ï´Ù. À¯Çà¿¡ ÀÇÇÑ °æ±â ħüÀÇ ¿µÇâÀ¸·Î ÀϺΠÁö¿ª¿¡¼´Â °Ç° °ü¸® ¿¹»êÀÌ ÁÙ¾îµé°í °³ÀÎ ¼Òºñµµ °¨¼ÒÇß½À´Ï´Ù. ÀÌ ¶§¹®¿¡ º´¿ø°ú °³ÀÎÀÌ ºñ¿ë Àý°¨À» µµ¸ðÇÏ´Â °¡¿îµ¥ Çã´Ï µå·¹½ÌÀ縦 Æ÷ÇÔÇÑ »óó ÄÉ¾î ¿ëǰ ½ÃÀå Àüü¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù.
¹Ì±¹ÀÇ FDA¿Í À¯·´ÀÇ EMA¿Í °°Àº ±â°ü¿¡ ÀÇÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©Àº Çã´Ï µå·¹½Ì ¾÷°èÀÇ È®´ë¿¡ Å« À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ´ç±¹Àº »óó Ä¡·á¸¦ À§ÇÑ ²ÜÀ» ±â¹ÝÀ¸·Î ÇÏ´Â Á¦Ç°À» Æ÷ÇÔÇÑ ÀÇ·á Á¦Ç°¿¡ ´ëÇÑ »ó¼¼ÇÑ ÀÓ»ó½ÃÇè°ú Æò°¡¸¦ ÅëÇØ È¿´É°ú ¾ÈÀü¼º¿¡ ´ëÇÑ ¾ö°ÝÇÑ Áõ°Å¸¦ ¿ä±¸ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦ ÇÁ·Î¼¼½ºÀÇ Ã¶ÀúÇϰí Àå±âÀûÀΠƯ¼ºÀº ½ÅÁ¦Ç° ½ÃÀå ÁøÀÔ Áö¿¬°ú »ý»ê ºñ¿ë »ó½ÂÀ» ÃÊ·¡ÇÏ¿© Çã´Ï µå·¹½Ì ½ÃÀåÀÇ ¼ºÀå Àü¸ÁÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. 2023³â 6¿ù, Medline Industries LP´Â Á¦Á¶¾÷ü·ÎºÎÅÍ ¸ê±Õ ¿ë·® °¨»çÀÇ ½ÇÆÐ°¡ º¸°íµÈ ÈÄ ISO 11137¿¡ µû¶ó ½ÇÆÐ ÈÄ ¿ë·®À» Áõ°¡½ÃŰÁö ¾Ê¾ÒÀ¸¸ç TheraHoney Wound GelÀ» ¸®ÄÝÇß½À´Ï´Ù.
Çã´Ï µå·¹½Ì ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- À¯Çüº°·Î ºñÁ¡Âø¼º ºÎ¹®Àº 2023³â¿¡ °¡Àå Å« ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇϸç 2024³âºÎÅÍ 2030³â±îÁö °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±× ÀÌÀ¯´Â º¸½À¼º°ú Ç×±Õ¼º¿¡ ÀÇÇØ »óó Ä¡À¯¸¦ ÃËÁøÇÏ°í °¨¿°·üÀÇ ÀúÇÏ¿Í Á¶Á÷ Àç»ýÀÇ ÃËÁø¿¡ µµ¿òÀÌ µÇ±â ¶§¹®ÀÔ´Ï´Ù.
- Á¦Ç°º°·Î, ²Ü ÇÔħ °ÅÁî´Â õ¿¬ Ç×±Õ Æ¯¼º, ½ÀÀ± »óó Ä¡À¯¸¦ ÃËÁøÇÏ´Â ´É·Â, ¸¸¼º »óó °ü¸®¿¡ ÀÖ¾î¼ÀÇ È¿´É¿¡ ÀÇÇØ 2023³â¿¡ 41.1%ÀÇ ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
- Çã´ÏÁ© ½ÃÆ® ºÐ¾ß´Â Ä¡À¯¿¡ µµ¿òÀÌ µÇ´Â ½ÀÀ± ȯ°æÀ» À¯ÁöÇÏ¸é¼ Æí¸®ÇÑ ºÎÂø ¹æ¹ýÀ» Á¦°øÇÔÀ¸·Î½á 2024³âºÎÅÍ 2030³â±îÁö °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- »óó À¯Çüº°·Î ¸¸¼º»óóºÐ¾ß°¡ 2023³â ÃÖ´ë ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß°í °í·ÉÈ ¹× ´ç´¢º´ µîÀÇ Áúȯ¿¡ µû¸¥ ¸¸¼º»óó ¹ß»ý·ü »ó½ÂÀ¸·Î 2024³âºÎÅÍ 2030³â±îÁö °¡Àå ³ôÀº CAGRÀÌ ¿¹ÃøµË´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â ȯÀÚÀÇ °á°ú¸¦ °³¼±Çϱâ À§ÇÑ Çõ½ÅÀûÀÎ »óó ÄÉ¾î ¼Ö·ç¼ÇÀÇ Ã¤¿ë¿¡ ÀÇÇØ º´¿ø ºÐ¾ß°¡ 2023³âÀÇ ¸ÅÃâ Á¡À¯À²¿¡¼ ¿ìÀ§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ²Ü ±â¹Ý µå·¹½Ì Àç·á°¡ º´¿ø ÇÁ·ÎÅäÄÝ¿¡ ÅëÇյǾî ÀÖ´Â °ÍÀº È¿°úÀûÀÎ »óó °ü¸® Àü·«À» ¼±È£ÇÏ´Â Áõ°Å¸¦ ±â¹ÝÀ¸·Î ÇÑ Áø·á·ÎÀÇ º¯È¸¦ ¹Ý¿µÇÕ´Ï´Ù.
- ¿Ü·¡ ȯÀÚ¿¡°Ô Çã´Ï µå·¹½ÌÀ» ¹èÆ÷Çϰí Àû¿ëÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ Ŭ¸®´Ð ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
- ºÏ¹Ì´Â ½ÃÀåÀ» µ¶Á¡Çϰí 2023³â¿¡´Â 42.3%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ½ÃÀåÀº »óó Äɾ À§ÇÑ ÀÚ¿¬ ¿ä¹ý°ú ´ëü ¿ä¹ý¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡·Î Å« ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Çã´Ï µå·¹½Ì ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ½ÃÀåÀÇ °úÁ¦ ºÐ¼®
- ½ÃÀå ±âȸ ºÐ¼®
- Çã´Ï µå·¹½Ì ½ÃÀå ºÐ¼® µµ±¸
- ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
- COVID-19ÀÇ ¿µÇ⠺м®
Á¦4Àå Çã´Ï µå·¹½Ì ½ÃÀå : À¯Çü ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ Çã´Ï µå·¹½Ì ½ÃÀåÀÇ À¯Çü º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ Çã´Ï µå·¹½Ì ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, À¯Çüº°, 2018-2030³â
- ºñÁ¡Âø
- Á¡Âø
Á¦5Àå Çã´Ï µå·¹½Ì ½ÃÀå : Á¦Ç° ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ Çã´Ï µå·¹½Ì ½ÃÀåÀÇ Á¦Ç° º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ Çã´Ï µå·¹½Ì ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Á¦Ç°º°, 2018-2030³â
- ²Ü ÇÔħ °ÅÁî
- Çã´Ï Á© ½ÃÆ®
- ²Ü ¿¬°í
- ²Ü º£À̽º ÆäÀ̽ºÆ®
Á¦6Àå Çã´Ï µå·¹½Ì ½ÃÀå : â»ó À¯ÇüÀÇ ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ Çã´Ï µå·¹½Ì ½ÃÀåÀÇ »óó À¯Çü º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ Çã´Ï µå·¹½Ì ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, »óó À¯Çüº°, 2018-2030³â
- ¸¸¼º »óó
- ±Þ¼º »óó
Á¦7Àå Çã´Ï µå·¹½Ì ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤ ¹× µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ Çã´Ï µå·¹½Ì ½ÃÀåÀÇ ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
- ¼¼°èÀÇ Çã´Ï µå·¹½Ì ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
- º´¿ø
- Ŭ¸®´Ð
- ÀçÅÃÄ¡·á
- Àå±â °£È£ ½Ã¼³
Á¦8Àå Çã´Ï µå·¹½Ì ½ÃÀå : Áö¿ª ÃßÁ¤ ¹× µ¿Ç⠺м®
- Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â, 2030³â
- Áö¿ª ½ÃÀå ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â:
- ºÏ¹Ì
- ºÏ¹Ì ½ÃÀå Ãß°è ¹× ¿¹Ãø, 2018-2030³â
- ¹Ì±¹
- ij³ª´Ù
- ¸ß½ÃÄÚ
- À¯·´
- À¯·´ ½ÃÀå Ãß°è ¹× ¿¹Ãø, 2018-2030³â
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- µ§¸¶Å©
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå Ãß°è ¹× ¿¹Ãø, 2018-2030³â
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- Çѱ¹
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- ¶óƾ¾Æ¸Þ¸®Ä« ½ÃÀå Ãß°è ¹× ¿¹Ãø, 2018-2030³â
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå Ãß°è ¹× ¿¹Ãø, 2018-2030³â
- ³²¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦9Àå °æÀï ±¸µµ
- ±â¾÷/°æÀïÀÇ ºÐ·ù
- Àü·« ¸ÅÇÎ
- ±â¾÷½ÃÀå Æ÷Áö¼Å´× ºÐ¼®, 2023³â
- ÁÖ¿ä ÀÎÁõ °ø±ÞÀÚ/ü°è ¼ÒÀ¯ÀÚ ¸ñ·Ï
- ±â¾÷ ÇÁ·ÎÆÄÀÏ/»óÀå ±â¾÷
- Comvita
- INTEGRA LIFESCIENCES
- Advancis Medical
- ManukaMed Ltd.
- Medline Industries, LP.
- Kastormed
- Cardinal Health
- HoffenCare Medical Inc
- Polyx Inc
- Dynarex Corporation
JHS
¿µ¹® ¸ñÂ÷
Honey Dressing Market Growth & Trends:
The global honey dressing market size is anticipated to reach USD 47.07 million by 2030, growing at a CAGR of 4.91% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is significantly driven by the increasing prevalence of chronic wounds and the growing awareness of the therapeutic benefits of honey in wound care. Chronic wounds, such as diabetic ulcers, venous leg ulcers, and pressure sores are becoming more common due to factors such as an aging population and rising incidences of diabetes. For instance, in January 2024, as per the American Heart Association (AHA), there are 9.7 million adults with undiagnosed diabetes and 29.3 million with a diagnosis of diabetes.
The increasing preference for natural and organic products among healthcare professionals and patients is a significant driver of the market. Honey has been recognized for its antimicrobial properties due to its high sugar content, low pH, and presence of hydrogen peroxide, making it effective against a wide range of pathogens. In March 2023, the International Wound Journal published a study that performed a meta-analysis to evaluate the impact of Honey Dressing (HD) on the treatment of Diabetic Foot Ulcers (DFU). It was found that the use of HD on DFUs resulted in a notably increased rate of wound healing and reduced the time needed for the wounds to heal, compared to the control group.
The COVID-19 pandemic had a significant impact on the market. The pandemic caused interruptions in the global supply chain, affecting the production and distribution of honey dressings. Lockdowns, restrictions on movement, and reduced workforce availability led to delays in manufacturing and shipping. With heightened awareness of infection control during the pandemic, there was increased interest in wound care products with antimicrobial properties. Honey dressings, known for their antibacterial effects, have seen some increased attention in specific segments of the market focused on preventing wound infections. The economic downturn caused by the pandemic led to reduced healthcare budgets and lower consumer spending in some regions. This affected the overall market for wound care products, including honey dressings, as hospitals and individuals sought to cut costs.
Strick regulatory frameworks set by entities like the FDA in the U.S. and the EMA in Europe pose significant barriers to the honey dressing industry's expansion. These authorities demand rigorous evidence of efficacy and safety through detailed clinical testing and assessments for medical products, including those based on honey for treating wounds. The exhaustive and protracted nature of these regulatory processes can result in delayed market entry for new products and elevate production expenses, thus hampering the growth prospects of the honey dressing market. In June 2023, Medline Industries LP recalled TheraHoney Wound Gel following a sterilization dose audit failure reported by the manufacturer, who did not increase the dose post-failure in accordance with ISO 11137.
Honey Dressing Market Report Highlights:
- Based on type, the non-adhesive segment held the largest revenue share in 2023 and is expected to grow at the highest CAGR from 2024 to 2030 due toits ability to promote wound healing through moisture retention and antibacterial properties, which help in reducing infection rates and enhancing tissue regeneration
- Based on product, the honey impregnated gauze segment dominated with a revenue share of 41.1% in 2023 due to its natural antibacterial properties, ability to promote moist wound healing, and its effectiveness in managing chronic wounds
- The honey gel sheets segment is expected to grow at the fastest CAGR from 2024 to 2030 owing to the convenient application method they provide while maintaining a moist environment conducive to healing
- Based on wound type, the chronic wounds segment held the largest revenue share in 2023 and is expected to grow at the highest CAGR from 2024 to 2030 due to the rising incidence of chronic wounds, associated with aging populations and conditions such as diabetes
- Based on end-use, the hospital segment dominated with a revenue share in 2023 due to their adoption of innovative wound care solutions to improve patient outcomes. The integration of honey-based dressings into hospital protocols reflects a shift towards evidence-based practices that prioritize effective wound management strategies
- The clinics segment is expected to grow at the fastest CAGR over the forecast period owing to their crucial role in the distribution and application of honey dressings for outpatient care
- North America dominated the market and accounted for a 42.3% share in 2023. The market is significantly influenced by the increasing awareness of natural and alternative therapies for wound care
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Type Segment
- 1.2.2. Product Segment
- 1.2.3. Wound Type Segment
- 1.2.4. End Use Segment
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
Chapter 3. Honey Dressing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rising prevalence of chronic wounds
- 3.2.1.2. Antimicrobial properties of honey
- 3.2.1.3. Consumer awareness
- 3.2.2. Market restraint analysis
- 3.2.2.1. Product recalls
- 3.2.2.2. Cost of products
- 3.2.3. Market challenges analysis
- 3.2.4. Market opportunities analysis
- 3.3. Honey Dressing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Honey Dressing Market: Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Honey Dressing Market Type Movement Analysis
- 4.3. Global Honey Dressing Market Size & Trend Analysis, by Type 2018 to 2030 (USD Million)
- 4.4. Non-Adhesive
- 4.4.1. Non-adhesive market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Adhesive
- 4.5.1. Adhesive market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Honey Dressing Market: Product Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Honey Dressing Market Product Movement Analysis
- 5.3. Global Honey Dressing Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 5.4. Honey Impregnated Gauze
- 5.4.1. Honey impregnated gauze market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Honey Gel Sheets
- 5.5.1. Honey gel sheets market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Honey Ointments
- 5.6.1. Honey ointments market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Honey-Based Pastes
- 5.7.1. Honey-based pastes market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Honey Dressing Market: Wound Type Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Honey Dressing Market Wound Type Movement Analysis
- 6.3. Global Honey Dressing Market Size & Trend Analysis, by Wound Type, 2018 to 2030 (USD Million)
- 6.4. Chronic Wounds
- 6.4.1. Chronic wounds market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Acute Wounds
- 6.5.1. Acute wounds market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Honey Dressing Market: End Use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global Honey Dressing Market End Use Movement Analysis
- 7.3. Global Honey Dressing Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 7.4. Hospitals
- 7.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Clinics
- 7.5.1. Clinics market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. Homecare Settings
- 7.6.1. Homecare settings market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7. Long-Term Care Facilities
- 7.7.1. Long-term care facilities market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Honey Dressing Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2023 & 2030
- 8.2. Regional Market Dashboard
- 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 8.4. North America
- 8.4.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.2. U.S.
- 8.4.2.1. Key country dynamics
- 8.4.2.2. Competitive scenario
- 8.4.2.3. Regulatory framework
- 8.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.3. Canada
- 8.4.3.1. Key country dynamics
- 8.4.3.2. Competitive scenario
- 8.4.3.3. Regulatory framework
- 8.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.4. Mexico
- 8.4.4.1. Key country dynamics
- 8.4.4.2. Competitive scenario
- 8.4.4.3. Regulatory framework
- 8.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5. Europe
- 8.5.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.2. UK
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Competitive scenario
- 8.5.2.3. Regulatory framework
- 8.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.3. Germany
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Competitive scenario
- 8.5.3.3. Regulatory framework
- 8.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.4. France
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Competitive scenario
- 8.5.4.3. Regulatory framework
- 8.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.5. Italy
- 8.5.5.1. Key country dynamics
- 8.5.5.2. Competitive scenario
- 8.5.5.3. Regulatory framework
- 8.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.6. Spain
- 8.5.6.1. Key country dynamics
- 8.5.6.2. Competitive scenario
- 8.5.6.3. Regulatory framework
- 8.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.7. Denmark
- 8.5.7.1. Key country dynamics
- 8.5.7.2. Competitive scenario
- 8.5.7.3. Regulatory framework
- 8.5.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.8. Sweden
- 8.5.8.1. Key country dynamics
- 8.5.8.2. Competitive scenario
- 8.5.8.3. Regulatory framework
- 8.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.9. Norway
- 8.5.9.1. Key country dynamics
- 8.5.9.2. Competitive scenario
- 8.5.9.3. Regulatory framework
- 8.5.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.2. Japan
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Competitive scenario
- 8.6.2.3. Regulatory framework
- 8.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.3. China
- 8.6.3.1. Key country dynamics
- 8.6.3.2. Competitive scenario
- 8.6.3.3. Regulatory framework
- 8.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.4. India
- 8.6.4.1. Key country dynamics
- 8.6.4.2. Competitive scenario
- 8.6.4.3. Regulatory framework
- 8.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.5. Australia
- 8.6.5.1. Key country dynamics
- 8.6.5.2. Competitive scenario
- 8.6.5.3. Regulatory framework
- 8.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.6. South Korea
- 8.6.6.1. Key country dynamics
- 8.6.6.2. Competitive scenario
- 8.6.6.3. Regulatory framework
- 8.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.7. Thailand
- 8.6.7.1. Key country dynamics
- 8.6.7.2. Competitive scenario
- 8.6.7.3. Regulatory framework
- 8.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7. Latin America
- 8.7.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.2. Brazil
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Competitive scenario
- 8.7.2.3. Regulatory framework
- 8.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.3. Argentina
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Competitive scenario
- 8.7.3.3. Regulatory framework
- 8.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8. MEA
- 8.8.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8.2. South Africa
- 8.8.2.1. Key country dynamics
- 8.8.2.2. Competitive scenario
- 8.8.2.3. Regulatory framework
- 8.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key country dynamics
- 8.8.3.2. Competitive scenario
- 8.8.3.3. Regulatory framework
- 8.8.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8.4. UAE
- 8.8.4.1. Key country dynamics
- 8.8.4.2. Competitive scenario
- 8.8.4.3. Regulatory framework
- 8.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8.5. Kuwait
- 8.8.5.1. Key country dynamics
- 8.8.5.2. Competitive scenario
- 8.8.5.3. Regulatory framework
- 8.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Company/Competition Categorization
- 9.2. Strategy Mapping
- 9.3. Company Market Position Analysis, 2023
- 9.4. List of Key Certification Providers/Scheme Owners
- 9.5. Company Profiles/Listing
- 9.5.1. Comvita
- 9.5.1.1. Company overview
- 9.5.1.2. Financial performance
- 9.5.1.3. Product benchmarking
- 9.5.1.4. Strategic initiatives
- 9.5.2. INTEGRA LIFESCIENCES
- 9.5.2.1. Company overview
- 9.5.2.2. Financial performance
- 9.5.2.3. Product benchmarking
- 9.5.2.4. Strategic initiatives
- 9.5.3. Advancis Medical
- 9.5.3.1. Company overview
- 9.5.3.2. Financial performance
- 9.5.3.3. Product benchmarking
- 9.5.3.4. Strategic initiatives
- 9.5.4. ManukaMed Ltd.
- 9.5.4.1. Company overview
- 9.5.4.2. Financial performance
- 9.5.4.3. Product benchmarking
- 9.5.4.4. Strategic initiatives
- 9.5.5. Medline Industries, LP.
- 9.5.5.1. Company overview
- 9.5.5.2. Financial performance
- 9.5.5.3. Product benchmarking
- 9.5.5.4. Strategic initiatives
- 9.5.6. Kastormed
- 9.5.6.1. Company overview
- 9.5.6.2. Financial performance
- 9.5.6.3. Product benchmarking
- 9.5.6.4. Strategic initiatives
- 9.5.7. Cardinal Health
- 9.5.7.1. Company overview
- 9.5.7.2. Financial performance
- 9.5.7.3. Product benchmarking
- 9.5.7.4. Strategic initiatives
- 9.5.8. HoffenCare Medical Inc
- 9.5.8.1. Company overview
- 9.5.8.2. Financial performance
- 9.5.8.3. Product benchmarking
- 9.5.8.4. Strategic initiatives
- 9.5.9. Polyx Inc
- 9.5.9.1. Company overview
- 9.5.9.2. Financial performance
- 9.5.9.3. Product benchmarking
- 9.5.9.4. Strategic initiatives
- 9.5.10. Dynarex Corporation
- 9.5.10.1. Company overview
- 9.5.10.2. Financial performance
- 9.5.10.3. Product benchmarking
- 9.5.10.4. Strategic initiatives
°ü·ÃÀÚ·á